BRPI1013777A2 - compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. - Google Patents
compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.Info
- Publication number
- BRPI1013777A2 BRPI1013777A2 BRPI1013777A BRPI1013777A BRPI1013777A2 BR PI1013777 A2 BRPI1013777 A2 BR PI1013777A2 BR PI1013777 A BRPI1013777 A BR PI1013777A BR PI1013777 A BRPI1013777 A BR PI1013777A BR PI1013777 A2 BRPI1013777 A2 BR PI1013777A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- receptor agonist
- cognitive disorders
- agonist compounds
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16874109P | 2009-04-13 | 2009-04-13 | |
| US29255910P | 2010-01-06 | 2010-01-06 | |
| PCT/US2010/030760 WO2010120695A2 (en) | 2009-04-13 | 2010-04-12 | 5-ht4 receptor agonist compounds for treatment of cognitive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1013777A2 true BRPI1013777A2 (pt) | 2016-04-05 |
| BRPI1013777A8 BRPI1013777A8 (pt) | 2017-09-19 |
Family
ID=42237213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013777A BRPI1013777A8 (pt) | 2009-04-13 | 2010-04-12 | Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8404711B2 (pt) |
| EP (1) | EP2419104B1 (pt) |
| JP (1) | JP2012523437A (pt) |
| KR (1) | KR20120017421A (pt) |
| CN (2) | CN105832735A (pt) |
| AU (1) | AU2010236734B2 (pt) |
| BR (1) | BRPI1013777A8 (pt) |
| CA (1) | CA2758321A1 (pt) |
| CY (1) | CY1119800T1 (pt) |
| DK (1) | DK2419104T3 (pt) |
| ES (1) | ES2654930T3 (pt) |
| HR (1) | HRP20180018T1 (pt) |
| HU (1) | HUE038141T2 (pt) |
| IL (1) | IL215660A0 (pt) |
| LT (1) | LT2419104T (pt) |
| MX (1) | MX2011010782A (pt) |
| NO (1) | NO2419104T3 (pt) |
| PL (1) | PL2419104T3 (pt) |
| PT (1) | PT2419104T (pt) |
| RU (1) | RU2569056C2 (pt) |
| SI (1) | SI2419104T1 (pt) |
| SM (1) | SMT201800036T1 (pt) |
| WO (1) | WO2010120695A2 (pt) |
| ZA (1) | ZA201107490B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CA2894860C (en) | 2008-11-19 | 2018-11-06 | Gerhard Koenig | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| MX357676B (es) | 2010-05-17 | 2018-07-18 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado. |
| EP3666272A1 (en) | 2012-05-08 | 2020-06-17 | Forum Pharmaceuticals Inc. | Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit |
| US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| JP6009080B2 (ja) | 2012-08-16 | 2016-10-19 | ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ | 老化及び認知症の予防及び／または治療活性を有する乳酸菌 |
| HUE053636T2 (hu) | 2017-05-24 | 2021-07-28 | H Lundbeck As | 5-HT6 receptor antagonista és acetilkolin-észteráz inhibitor kombinációja Alzheimer-kór kezelésében történõ alkalmazásra ApoE4 alléleket hordozó betegek szubpopulációjában |
| CN110545812A (zh) | 2017-06-01 | 2019-12-06 | 卫材R&D管理有限公司 | 包含pde9抑制剂的药物组合物 |
| BR112019024851A2 (pt) | 2017-06-02 | 2020-06-09 | Fujifilm Toyama Chemical Co Ltd | agente para evitar ou tratar atrofia cerebral |
| MA49754B1 (fr) | 2017-07-31 | 2024-10-31 | Alfasigma S.P.A. | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001066114A1 (en) * | 2000-03-03 | 2001-09-13 | Eisai Co., Ltd. | Novel methods using cholinesterase inhibitors |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2010
- 2010-04-12 BR BRPI1013777A patent/BRPI1013777A8/pt not_active IP Right Cessation
- 2010-04-12 MX MX2011010782A patent/MX2011010782A/es active IP Right Grant
- 2010-04-12 CN CN201610257689.5A patent/CN105832735A/zh active Pending
- 2010-04-12 CN CN2010800164976A patent/CN102395371A/zh active Pending
- 2010-04-12 HU HUE10713790A patent/HUE038141T2/hu unknown
- 2010-04-12 PL PL10713790T patent/PL2419104T3/pl unknown
- 2010-04-12 CA CA2758321A patent/CA2758321A1/en not_active Abandoned
- 2010-04-12 WO PCT/US2010/030760 patent/WO2010120695A2/en not_active Ceased
- 2010-04-12 SM SM20180036T patent/SMT201800036T1/it unknown
- 2010-04-12 AU AU2010236734A patent/AU2010236734B2/en not_active Ceased
- 2010-04-12 RU RU2011146032/15A patent/RU2569056C2/ru not_active IP Right Cessation
- 2010-04-12 JP JP2012504924A patent/JP2012523437A/ja active Pending
- 2010-04-12 HR HRP20180018TT patent/HRP20180018T1/hr unknown
- 2010-04-12 PT PT107137903T patent/PT2419104T/pt unknown
- 2010-04-12 KR KR1020117026729A patent/KR20120017421A/ko not_active Ceased
- 2010-04-12 EP EP10713790.3A patent/EP2419104B1/en active Active
- 2010-04-12 DK DK10713790.3T patent/DK2419104T3/en active
- 2010-04-12 NO NO10713790A patent/NO2419104T3/no unknown
- 2010-04-12 SI SI201031632T patent/SI2419104T1/en unknown
- 2010-04-12 US US12/758,631 patent/US8404711B2/en not_active Expired - Fee Related
- 2010-04-12 LT LTEP10713790.3T patent/LT2419104T/lt unknown
- 2010-04-12 ES ES10713790.3T patent/ES2654930T3/es active Active
-
2011
- 2011-10-10 IL IL215660A patent/IL215660A0/en unknown
- 2011-10-12 ZA ZA2011/07490A patent/ZA201107490B/en unknown
-
2013
- 2013-02-20 US US13/771,685 patent/US20140057939A1/en not_active Abandoned
-
2018
- 2018-01-19 CY CY20181100069T patent/CY1119800T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL215660A0 (en) | 2012-01-31 |
| CN105832735A (zh) | 2016-08-10 |
| RU2569056C2 (ru) | 2015-11-20 |
| US8404711B2 (en) | 2013-03-26 |
| CN102395371A (zh) | 2012-03-28 |
| EP2419104B1 (en) | 2017-11-08 |
| MX2011010782A (es) | 2012-01-20 |
| RU2011146032A (ru) | 2013-05-20 |
| PT2419104T (pt) | 2018-01-31 |
| CA2758321A1 (en) | 2010-10-21 |
| JP2012523437A (ja) | 2012-10-04 |
| DK2419104T3 (en) | 2018-02-05 |
| AU2010236734A1 (en) | 2011-11-03 |
| AU2010236734B2 (en) | 2015-06-11 |
| CY1119800T1 (el) | 2018-06-27 |
| KR20120017421A (ko) | 2012-02-28 |
| ES2654930T3 (es) | 2018-02-15 |
| LT2419104T (lt) | 2018-02-12 |
| PL2419104T3 (pl) | 2018-04-30 |
| SI2419104T1 (en) | 2018-03-30 |
| AU2010236734A8 (en) | 2012-02-16 |
| BRPI1013777A8 (pt) | 2017-09-19 |
| US20140057939A1 (en) | 2014-02-27 |
| SMT201800036T1 (it) | 2018-03-08 |
| US20100261752A1 (en) | 2010-10-14 |
| WO2010120695A3 (en) | 2010-12-02 |
| EP2419104A2 (en) | 2012-02-22 |
| HUE038141T2 (hu) | 2018-10-29 |
| NO2419104T3 (pt) | 2018-04-07 |
| ZA201107490B (en) | 2012-06-27 |
| WO2010120695A2 (en) | 2010-10-21 |
| HRP20180018T1 (hr) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0912362A2 (pt) | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos | |
| ZA201107490B (en) | 5-ht4 receptor agonist compounds for treatment of cognitive disorders | |
| BRPI0918527A2 (pt) | compostos para o tratamento de disturbios do cns | |
| UY33094A (es) | Procedimiento para la preparacion de dronedarona | |
| BR112012013260A2 (pt) | dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa | |
| BRPI1015250A2 (pt) | métodos de estabilização e de hidrogenação para olefinas micróbio-derivadas | |
| IL225758A0 (en) | Preparations containing combinations of serotonin agonists and their uses | |
| BR112013014943A2 (pt) | compostos úteis para o tratamento de aids | |
| DK2440230T3 (da) | Behandlingsregimener til behandling af neurologisk sygdom | |
| BRPI0813516A2 (pt) | Tratamento de distúrbios proliferativos de células b | |
| BRPI1015274A2 (pt) | instalação para o tratamento de superfície de peças | |
| BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
| BRPI1007404A2 (pt) | método para síntese de (1s,2r)-milnaciprano | |
| BRPI0924916A2 (pt) | Equipamento para atenção integral de neonatos críticos. | |
| BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas | |
| HUE033690T2 (hu) | Terápiás szer hangulatzavarokra | |
| BR112013012072A2 (pt) | derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos | |
| PT2623499E (pt) | Derivado de 1,2,4-triazolona para tratamento de distúrbios de humor | |
| BRPI1008008A2 (pt) | usos de antagonistas do receptor de nk | |
| EP2540721A4 (en) | GHRELIN RECEPTOR AGONIST FOR DYSKRASY TREATMENT | |
| BRPI0812034A2 (pt) | Combinações de neramexano para o tratamento de distúrbios neurodegenerativos | |
| EP2552423A4 (en) | STABILIZED FORMULATIONS OF CNS COMPOUNDS | |
| PT2467140T (pt) | Lapatinib para tratamento do cancro | |
| BRPI0915761A2 (pt) | composto de heterociclila para tratamento de doença cardiovascular | |
| BR112012002267A2 (pt) | compostos para o tratamento de inflamação. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |